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Background: To date, no therapeutic option has been established for sudden deafness refractory to systemic
corticosteroids. This study aimed to examine the efficacy and safety of topical insulin-like growth factor-1 (IGF-1)
therapy in comparison to intratympanic corticosteroid therapy.
Methods: We randomly assigned patients with sudden deafness refractory to systemic corticosteroids to receive
either gelatin hydrogels impregnated with IGF-1 in the middle ear (62 patients) or four intratympanic injections with
dexamethasone (Dex; 58 patients). The primary outcome was the proportion of patients showing hearing improvement
(10 decibels or greater in pure-tone average hearing thresholds) 8 weeks after treatment. The secondary outcomes
included the change in pure-tone average hearing thresholds over time and the incidence of adverse events.
Results: In the IGF-1 group, 66.7% (95% confidence interval [CI], 52.9–78.6%) of the patients showed hearing
improvement compared to 53.6% (95% CI, 39.7–67.0%) of the patients in the Dex group (P = 0.109). The difference in
changes in pure-tone average hearing thresholds over time between the two treatments was statistically significant
(P = 0.003). No serious adverse events were observed in either treatment group. Tympanic membrane perforation did
not persist in any patient in the IGF-1 group, but did persist in 15.5% (95% CI, 7.3–27.4%) of the patients in the Dex
group (P = 0.001).
Conclusions: The positive effect of topical IGF-1 application on hearing levels and its favorable safety profile suggest
utility for topical IGF-1 therapy in patients with sudden deafness.
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Sudden sensorineural hearing loss (SSHL), an unexplained
unilateral hearing loss with an onset of less than 72 h, is a
common disease with acute onset hearing impairment.
The incidence of SSHL is reportedly 5 to 20 patients per
100,000 persons per year [1]. Approximately 35,000 pa-
tients with SSHL consult a doctor each year in Japan [2].
The standard treatment for SSHL is systemic corticoster-
oid treatment [3,4]. Hearing improvement after systemic
corticosteroids occurs in 50% of the patients, but approxi-
mately 20% of the patients show no response [5]. Further,
systemic corticosteroid treatment often causes adverse
events [6] that can occasionally be life-threatening [7]. As
an alternative for systemic corticosteroids, intratympanic
corticosteroid treatment by direct injection into the mid-
dle ear has recently gained wide popularity because of the
low risk for systemic adverse events and because of the
potential delivery of high concentrations of a corticoster-
oid into the inner ear [8]. Intratympanic corticosteroid
therapy is commonly used for the treatment of SSHL, after
the failure of systemic corticosteroid treatment [9-15].
However, the supporting evidence for its use is weak be-
cause of the limitation in the study design and power [16].
A major difficulty in treating sensorineural hearing
loss is the poor regeneration capacity of the mammalian
cochlea. Therefore, protecting the cochlea from irrevers-
ible degeneration is a practical strategy. Several growth
factors have been investigated for their protective effects
on the sensory hair cells of the cochlea [17,18]. The focus
of this study was on insulin-like growth factor-1 (IGF-1),
which has been used for the treatment of insulin-resistant
diabetes and dwarfism. IGF-1 also plays crucial roles in
both the development and maintenance of the cochlea
[19,20]. We used a gelatin hydrogel, which enables the
sustained release of proteins or peptides, for the delivery
of IGF-1 into the cochlear fluid [21]. We previously per-
formed a successful series of animal experiments using
this method [21,22]. A prospective, single-armed clinical
trial in patients with SSHL refractory to systemic cortico-
steroids was then performed, the results of which indi-
cated the safety and efficacy of topical IGF-1 therapy in
comparison to the historical control of hyperbaric oxygen
therapy [23].
The goal of the current study was to investigate the ef-
ficacy and safety of topical IGF-1 therapy as a novel
therapeutic option for SSHL. We conducted a multicen-
ter, randomized clinical trial to compare topical IGF-1
therapy and intratympanic corticosteroid therapy for
treating SSHL refractory to systemic corticosteroids.
Methods
Study design and patients
This was a multicenter, randomized, open, parallel-group
trial. The study was conducted from November 2010through October 2013 at 9 tertiary referral hospitals in
Japan. The trial followed the guiding principles of the
Declaration of Helsinki. The study protocol, manual of
procedures, and informed consent form were approved by
the institutional review boards of all participating sites
(Ethical Committee of the Graduate School of Medicine,
Kyoto University [C470], Ethical Committee of the Gradu-
ate School of Medicine, Hirosaki University [2011–145],
Ethical Committee of University of Tsukuba Hospital
[H23-13], Ethical Committee of Toranomon Hospital
[2011-4-15], Ethical Committee of Shinshu University
Hospital [1705], Ethical Committee of Nagoya City Uni-
versity Hospital [45-11-0005], Ethical Committee of Kobe
City Medical Center General Hospital [1], Ethical Com-
mittee of Ehime University Hospital [1105003], and Eth-
ical Committee of the Graduate School of Medicine,
Kyushu University [23011]). All patients provided written
informed consent. Eligible participants were all adults,
20 years or older, who had SSHL defined as a unilateral
sensorineural hearing loss of at least 30 decibels (dB)
sound pressure level (SPL) over at least three test frequen-
cies that developed within 3 days. They also met the fol-
lowing eligibility criteria: they had been diagnosed as
having SSHL within 25 days of onset; they presented with
an abnormality in the distortion product of otoacoustic
emissions; and they showed less than 30 dB hearing im-
provement in the mean hearing level, based on pure-tone
audiometry (PTA) at five tested frequencies (0.25 kHz,
0.5 kHz, 1.0 kHz, 2.0 kHz, and 4.0 kHz) after more than
7 days of systemic corticosteroid treatment. Similar to our
previous trial [23], we excluded patients with active
chronic otitis media, acute otitis media, otitis media with
effusion or dysfunction of the auditory tube, malignant tu-
mors, and systemic diseases. All patients underwent im-
aging examinations to rule out retrocochlear pathology.
Randomization and masking
Patients were randomly assigned (1:1) to receive either
topical IGF-1 therapy or intratympanic dexamethasone
(Dex) therapy. Randomization was performed centrally
with stratification by the study sites and the mean hear-
ing thresholds, based on the PTA at the five frequencies
tested at registration (lower than 90 dB SPL vs. 90 dB
SPL or higher). The randomization sequence was gener-
ated by a third-party contract clinical research organiza-
tion (independent from the trial investigators). Local
investigators used a web-based system during enrolment,
which then automatically assigned patients to either treat-
ment group. Besides central randomization, no further
masking was used in this open-label study.
Procedures
The treatment was performed within 7 days of enrolment
and systemic corticosteroid treatment was completed by
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from porcine skin gelatin (Nitta Gelatin Inc., Osaka,
Japan), based on a previously described method [23,24].
Mecasermin (Somazon [10 mg for injection]; Astellas
Pharma, Inc., Tokyo, Japan), a recombinant human IGF-1,
was dissolved in physiological saline at a final concentra-
tion of 10 mg/mL. Sixty minutes before application, a
30 μL sample of mecasermin solution was mixed with
3 mg of gelatin hydrogel. After tympanostomy under local
anesthesia with 1% lidocaine, the hydrogel (which con-
tained 300 μg of mecasermin) was placed in the round
window niche of the middle ear; a single application was
used. The control group received four 0.5 mL doses con-
taining 3.8 mg/mL dexamethasone sodium phosphate
(Orgadrone injection [1.9 mg]; MSD, Inc., Tokyo, Japan)
that was injected into the middle ear through the tym-
panic membrane. In the literature [9-15], a variety of regi-
mens for intratympanic injections of corticosteroids have
been used. Considering practical use in common clinical
settings, we chose four doses. Injections were performed
over 4 consecutive days in principle. Within at least 7 days,
four injections were administered. Patients were placed in
the supine position with the affected ear slightly raised
and remained in this position for 30 min after the injec-
tion. For 16 weeks after treatment, the patients were ex-
amined at the outpatient clinics of the participating sites.
The PTA was measured on the day of enrolment, and then
at 1, 2, 4, 8, 12, and 16 weeks after treatment. During the
observation period, which totaled 16 weeks, all adverse
events were recorded.
Outcomes
The primary outcome measure was the proportion of
patients showing hearing improvement of 10 dB or
greater in the mean hearing level. Hearing improvement
was based on PTA at five tested frequencies and was de-
fined as better than slight recovery, based on the criteria
for hearing improvement determined by the Sudden
Deafness Research Committee of the Japanese Ministry
of Health, Labor and Welfare in 1984 (Table 1) atTable 1 Criteria for hearing improvement determined by
Sudden Deafness Research Committee of the Japanese
Ministry of Health, Labour and Welfare in 1984
Complete recovery Recovery of a hearing level within 20 decibels (dB)
at all five frequencies tested (0.25, 0.5, 1.0, 2.0 and
4.0 kHz) or recovery to the same level as the
opposite side in pure-tone auditometry
Marked recovery 30 dB and over recovery in the mean hearing level
at the five frequencies tested
Slight recovery Recovery of better than 10 dB and less than 30 dB
in the mean hearing level at the five frequencies
tested
No response Less recovery than 10 dB in the mean hearing level
at the five frequencies tested8 weeks after treatment. Briefly, the complete recovery
includes patients showing recovery of a hearing level
within 20 dB SPL or to the similar level to the opposite
side, the marked recovery is more than 30 dB recovery,
and the no recovery is less recovery than 10 dB. Second-
ary outcome measures included the change in the pure-
tone average hearing thresholds over time (i.e., from the
first audiogram to the 16-week follow-up audiogram),
the proportion of patients showing hearing improvement
at 12 and 16 weeks after treatment, and the incidence of
adverse events during the observation period. In
addition to checking vital signs in the physical examin-
ation at each visit, laboratory studies were performed at
registration, and then at 1 week, 8 weeks, and 16 weeks
after treatment.
Statistical analysis
The null hypothesis was that the effect of topical IGF-1
treatment on the proportion of patients showing hearing
improvement would not be superior to intratympanic in-
jection of Dex. The sample size was determined based
on our previous findings and on published papers. In
our previous clinical trial of topical IGF-1 therapy, no
patient that had been enrolled later than 26 days after
sudden hearing loss recovered their hearing [23]. The
proportion of patients with hearing improvement after
topical IGF-1 treatment was 62.5% (10 of 16 patients) at
12 weeks and 68.8% (11 of 16 patients) at 24 weeks,
using the eligibility criteria of patients with SSHL within
25 days after onset of sudden hearing loss. Based on
these findings, we hypothesized that the expected pro-
portion of patients showing hearing improvement with
topical IGF-1 therapy would be 65%. To determine the
expected proportion of patients showing hearing im-
provement for intratympanic Dex therapy, we referred
to the information in several publications [9-15] that
were available in October 2010 and used the following
criteria: i) the sample size had more than 10 participants
and ii) intratympanic Dex therapy was a salvage treat-
ment (Table 2). In these previous reports, the mean pro-
portion of patients showing hearing improvement was
39% (range, 21–58%). Therefore, the proportion of pa-
tients who would show hearing improvement with intra-
tympanic Dex therapy was expected to be approximately
40%. The sample size was based on the continuity-
adjusted arcsine test with a one-sided significance level
of 0.05 and a power of 0.80. The required sample size
was 120 participants, assuming that 5% of the patients
would be excluded from the analysis.
All statistical analyses were performed on an intention-
to-treat basis. The safety analyses were conducted on all
patients who underwent randomization and received at
least one dose of the study drugs. Efficacy was analyzed in
all patients except those who had been excluded from the
Table 2 Previous studies of intratympanic dexamethasone therapy as a salvage treatment
No. of patients PTA recovery Dexamethasone concentration Doses Proportion of recovery (%)
Ho et al. [9] 15 28 dB 4 mg/mL 3 doses, once a week 53%
Choung et al. [10] 34 9 dB 5 mg/mL 4 doses, twice a week 39%
Roebuck et al. [11] 31 12 dB 24 mg/mL Single 29%
Haynes et al. [12] 40 5 dB 24 mg/mL Single 27.5%
Plontke et al. [13] 11 14 dB 4 mg/mL Pump for 14 days 45%
Kakehata et al. [14] 24 17 dB 4 mg/mL 15 doses 58%
Lee et al. [15] 34 NA 4 mg/mL 6 doses for 14 days 21%
Mean (95% CI) 27 (21–33) 39% (30%–48%)
PTA, Pure-tone audiometry; NA, Not available; CI, Confidential interval.
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between treatments in the proportion of patients showing
hearing improvement at 8, 12, and 16 weeks after treat-
ment were evaluated with Fisher’s exact test at a one-sided
significance of 0.05. The difference between treatments in
changes in pure-tone average hearing thresholds over time
was investigated with repeated measures linear mixed
model containing terms for treatment, time, and treatment-
by-time interaction with an unstructured covariance struc-
ture [25]. The effect of treatment-by-treatment interaction
was analyzed with the t-test at a one-sided significance of
0.05. The differences between treatments in the incidence
of adverse events and in the baseline characteristics were
analyzed with either Fisher’s exact test or the t-test at a
two-sided significance of 0.05. Statistical analyses were
performed by using SAS version 9.3 software (SAS Insti-
tute, Inc., Cary, NC, USA).
Results
Study overview
Patients from nine participating sites were enrolled be-
tween March 2011 and October 2013. The recruitment120 Randomize
62 Randomized to topical IGF-1
60 Received topical IGF-1 as randomized
2 Withdrew consent
59 Completed intervention
1 Excluded owing to examiner error
57 Included in primary outcome analysis
2 Missed 8-w follow-up
Figure 1 Study overview.and enrollment period was originally planned to close in
February 2013, but it was extended to meet the recruit-
ment targets. There were 120 patients who consented to
participate (Figure 1). All patients were randomized to
either the IGF-1 group or the Dex group; 118 patients
were included in the safety analysis (60 IGF-1, 58 Dex)
because 2 patients from the IGF-1 group withdrew con-
sent. Of the 118 patients who were included, 4 patients
completed the treatments, but missed the 8-week
follow-up (2 IGF-1, 2 Dex) and 1 patient was excluded
owing to examiner error (1 IGF-1).
Baseline characteristics were comparable between the
two treatment groups (Table 3). Between the IGF-1 and
Dex groups, no significant baseline differences in demo-
graphics, physical characteristics, ear examination, or
PTA thresholds were found except the proportion of pa-
tients presenting with aural fullness (Table 3). The mean
age of all participants was 49.3 years, and 45.8% of the
participants were male. The mean PTA thresholds in the
affected and unaffected ears were 85.2 dB SPL (95% con-
fidence interval [CI], 81.3–89.1) and 18.1 dB SPL (95%
CI, 14.9–21.3), respectively. The mean number of daysd
58 Randomized to intratympanic Dex
58 Received intratympanic Dex as randomized
58 Completed intervention 
56 Included in primary outcome analysis
2 Missed 8-w follow-up
Table 3 Baseline characteristics of patients
Characteristics Intratympanic Dex (n = 58) Topical IGF-1 (n = 60) P value
Age-yr, mean ± SD 50.1 ± 13.0 48.6 ± 14.0 0.557
Male sex-no. (%) 26 (44.8) 28 (46.7) 0.855
No. of days for study entry from onset, mean (95% CI) 16.3 (15.1–17.5) 15.8 (14.6–17.0) 0.574
Hearing improvement by pre-treatment-no. (%)
>10 dB, <30 dB 13 (22.4) 17 (28.3) 0.528
<10 dB 45 (77.6) 43 (71.7)
Hearing-dB pure-tone average, mean (95% CI)
Affected ear 84.8 (79.1–90.4) 85.6 (80.0–91.2) 0.835
Unaffected ear 15.8 (12.4–19.2) 20.4 (15.0–25.7) 0.160
Other symptoms-no. (%)
Dizziness/Vertigo 23 (39.7) 31 (51.7) 0.202
Tinnitus 49 (84.5) 51 (85) >0.999
Aural fullness 44 (75.9) 32 (53.3) 0.013*
An asterisk indicates statistical significance with Fisher’s exact test. Dex: dexamethasone.
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CI, 15.2–16.9). At enrolment, dizziness or vertigo was
present in 45.8% of the patients, tinnitus was present in
84.8% of the patients, and aural fullness was present
64.4% of the patients.
Primary outcome
The primary outcome was the proportion of patients
showing hearing improvement (10 dB or greater in pure-
tone average hearing thresholds) at 8 weeks after treat-
ment. In the Dex group, 53.6% (95% CI, 39.7–67.0%) of
patients showed hearing improvement at 8 weeks after
treatment, whereas in the IGF-1 group, 66.7% (95% CI,
52.9–78.6%) of patients showed hearing improvement
(Table 4). The null hypothesis for the primary outcome
was not rejected (P = 0.109). However, a trend was ob-
served in the higher proportion of patients in the IGF-1
group showing complete or marked recovery (30 dB or
greater in pure-tone average hearing thresholds) over that
in the Dex group (Table 2).
Secondary outcomes
The changes in the pure-tone average hearing thresholds
occurring over time in both treatments are shown in
Figure 2. The difference in the changes in the pure-tone
average hearing thresholds over time between the treat-
ments was statistically significant with repeated measures
linear mixed model containing terms for treatment, time,
and treatment-by-time interaction with an unstructured
covariance structure (the effect for the interaction term
[standard error]: −0.28 [0.10], P = 0.003). This demon-
strated that pure-tone average hearing thresholds of the
IGF-1 group significantly reduced over time, if changes in
pure-tone average hearing thresholds over time in the Dex
group were set to zero.The proportions of patients showing hearing improve-
ment (i.e., 10 dB or greater) at 12 weeks and 16 weeks
after treatment were estimated as the secondary out-
comes (Table 4). The null hypothesis for the proportions
of patients showing hearing improvement at 12 weeks or
16 weeks after treatment was not rejected (P = 0.066 for
12 weeks; P = 0.116 for 16 weeks). At 12 and 16 weeks
after treatment, there was a trend in the IGF-1 group
showing a larger number of patients with complete and
marked recovery when compared to the Dex group
(Table 4).
Adverse events
No serious adverse events were observed in either treat-
ment group. During the observation period, moderate
adverse events occurred in 43.1% (95% CI, 30.2–56.8) of
the patients in the Dex group and in 35.0% (95% CI,
23.1–48.4) of the patients in the IGF-1 group (Table 4).
No significant difference in the incidence of adverse
events was found between treatments (P = 0.452). Most
adverse events, such as otitis media, otitis externa, tin-
nitus, and nausea or vomiting disappeared during the
observation period. However, tympanic membrane per-
foration persisted in 15.5% (95% CI, 7.3–27.4%) of the
patients in the Dex group at the end of the observation
period. On the other hand, no patient in the IGF-1
group showed residual perforation in the tympanic mem-
brane. The difference in the incidence of tympanic mem-
brane perforation was statistically significant (P = 0.001).
Discussion
This is the first randomized controlled clinical trial to
test the efficacy of a growth factor for the treatment of
sensorineural hearing loss. In the current study, we lo-
cally applied IGF-1 to patients with SSHL refractory to
Table 4 Primary and secondary outcomes
Intratympanic Dex Topical IGF-1 P value
Primary outcome
Proportion of patients showing hearing recovery at 8 weeks 53.6% (30/56) 66.7% (38/57) 0.109
[95% CI: 39.7–67.0] [95% CI: 52.9–8.6]
Complete recovery 0.0% (0/56) 3.5% (2/57)
Marked recovery 16.1% (9/56) 24.6% (14/57)
Slight recovery 37.5% (21/56) 38.6% (22/57)
No recovery 46.4% (26/56) 33.3% (19/57)
Secondary outcomes
Proportion of patients showing hearing recovery at 12 weeks 55.4% (31/56) 70.7% (41/58) 0.066
[95% CI: 41.5–68.7] [95% CI: 57.3–81.9]
Complete recovery 0.0% (0/56) 5.2% (3/58)
Marked recovery 21.4% (12/56) 31.0% (18/58)
Slight recovery 33.9% (19/56) 34.5% (20/58)
No recovery 44.6% (25/56) 29.3% (17/58)
Proportion of patients showing hearing recovery at 16 weeks 54.7% (29/53) 67.9% (36/53) 0.116
[95% CI: 40.4–68.4] [95% CI: 53.7–80.1]
Complete recovery 0.0% (0/53) 5.7% (3/53)
Marked recovery 22.6% (12/53) 24.5% (13/53)
Slight recovery 32.1% (17/53) 37.7% (20/53)
No recovery 45.3% (24/53) 32.1% (17/53)
Adverse events
Serious 0.0% (0/58) 0.0% (0/59) >0.999
Non-serious 43.1% (25/58) 35.0% (21/59) 0.452
Tympanic membrane perforation 15.5% (9/58) 0.0% (0/59) 0.001*
Otitis media 1.7% (1/58) 6.8% (4/59) 0.364
Otitis externa 0.0% (0/58) 1.7% (1/59) >0.999
Tinnitus 8.6% (5/58) 0.0% (0/59) 0.027*
Nausea/Vomit 3.4% (2/58) 3.4% (2/59) >0.999
Others 24.1% (14/58) 30.5% (18/59) 0.535
Asterisks indicate statistical significance with Fisher’s exact test.
Nakagawa et al. BMC Medicine 2014, 12:219 Page 6 of 8
http://www.biomedcentral.com/1741-7015/12/219systemic steroids. The null hypothesis of the primary
outcome was that the proportion of patients showing
hearing improvement after topical IGF-1 therapy would
not be better than that after intratympanic Dex therapy.
The null hypothesis was not rejected in the present
study. The major reason for this is an unexpectedly high
proportion of patients showing hearing improvement
after intratympanic Dex therapy. The proportion of pa-
tients showing hearing improvement after topical IGF-1
therapy was 66.7 to 70.7%, which was nearly identical to
our hypothesized value of 65%, whereas the proportion
of patients showing hearing improvement after intratym-
panic Dex therapy (range, 53.6– 55.4%) was higher than
our hypothesized value of 40%.
Although the null hypothesis for the primary outcome
was not rejected, this randomized controlled trial showedsignificantly better recovery of pure-tone average thresh-
olds over time in the IGF-1 group, compared to the Dex
group. In addition, a trend that the proportion of patients
in the IGF-1 group who showed complete or marked re-
covery was higher than that in the Dex group was ob-
served at 8, 12, or 16 weeks after treatment. Complete
recovery of hearing was observed only in the IGF-1 group.
These findings strongly suggest the superior efficacy of
topical IGF-1 therapy over intratympanic Dex therapy.
In the current study, we used intratympanic cortico-
steroid therapy as a control treatment because it has
widely been accepted as a salvage treatment for SSHL
refractory to systemic corticosteroids [9-15]. The current
randomized study also provided evidence for the safety
and efficacy of intratympanic Dex therapy for SSHL re-









































Figure 2 Changes in pure-tone average hearing thresholds over
time. The difference between IGF-1 and dexamethasone (Dex)
treatments in changes in pure-tone average hearing thresholds over
time was statistically significant. Captions in the graph show mean
values. Bars represent 95% confidence intervals.
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curred in the Dex patient group. However, tympanic
membrane perforation persisted in 15.5% of these pa-
tients, while tympanic membrane perforation was absent
in the IGF-1 patient group. The incidence of tympanic
membrane perforation in the Dex group in the present
study was higher than the 3.9% incidence in a previous
randomized trial of intratympanic corticosteroid therapy
as the initial treatment [8]. This may be because of a dif-
ference in either the application regimen or the influ-
ence of the preceding systemic corticosteroid treatment.
It is important to note that intratympanic injection of
corticosteroids causes tympanic membrane perforation
in a certain proportion of treated patients, while both
our previous [23] and present results demonstrated no
occurrence of residual perforation in tympanic mem-
branes of patients treated with topical IGF-1 therapy.
This indicated the superior safety of topical IGF-1 ther-
apy over intratympanic Dex therapy. On the other hand,
the high incidence of tympanic membrane perforation in
the Dex group might affect hearing recovery outcomes
in the Dex group.
The present findings indicate the efficacy and safety of
topical IGF-1 therapy for SSHL. However, topical IGF-1
therapy requires surgical procedures and causes uncom-
fortable symptoms associated with the local application.
In addition, spontaneous recovery of hearing occurs in
30 to 60% of patients with SSHL [5,26-28]. Therefore,
with the need for balancing the harmful side effects and
the benefits, SSHL patients showing insufficient hearing
improvement after the administration of oral corticoste-
roids or after strict observation for 7 days may be goodcandidates for topical IGF-1 therapy. On the other hand,
IGF-1 is a promoter of cell proliferation in some cellular
contents. Therefore, a long-term follow-up of patients
may be required. Of note, in our previous clinical trial,
we locally applied IGF-1 in the middle ear of 25 patients
with refractory SSHL [23]; in the 5-year follow-up, no
tumor formation was identified in those patients.Conclusions
We performed a randomized, controlled clinical trial of
topical IGF-1 therapy in patients with SSHL refractory
to systemic corticosteroids and compared this treatment
to intratympanic corticosteroid therapy. Present results
suggest the possibility that IGF-1 is superior to intratym-
panic Dex therapy, but the current study design failed to
confirm this possibility. The positive effect of topical
IGF-1 application on hearing levels and its favorable
safety profile suggest utility for topical IGF-1 therapy as
a salvage treatment for SSHL.
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